Lillian Gien, MD, spoke about continued use of immunotherapy in patients with recurrent clear cell carcinoma of the ovary following results of a trial examining pembrolizumab plus epacadostat.
Lilian Gien, MD
Advertisement
Articles by Lilian Gien, MD
At 2022 IGCS, Lilian Gien, MD, spoke about a phase 2 trial which analyzed pembrolizumab plus epacadostat in patients with recurrent clear cell carcinoma of the ovary.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
2
SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC
3
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
4
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
5
